BioSpace News Archive

Abivax SA (Euronext Paris: FR0012333284 - ABVX) (“Abivax” or the “Company”) today announced the formal commencement of book-building and the filing of an amended registration statement on Form F-1, including an estimated initial public offering price range, in connection with its intention to issue, subject to market and other conditions, approximately 20,325,500 ordinary shares.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced a publication in the journal Vaccine entitled “Vaccine microarray patch self-administration: An innovative approach to improve pandemic and routine vaccination rates.”

Immuron Limited is pleased to announce the second cohort of 34 participants have commenced the clinical trial to evaluate the efficacy of Travelan® to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli.

TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The New England Journal of Medicine

Telix Pharmaceuticals Limited issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 September 2023.

Gero, a biotechnology company focused on aging and chronic diseases, has closed $6M in a Series A extension round.

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced the U.S. Food and Drug Administration granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington’s disease.

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that TheJournal of Infectious Diseases has published preclinical data on HB-400, an investigational therapeutic vaccine for chronic hepatitis B developed in collaboration with Gilead Sciences, Inc.

Generation Bio Co. today announced the development of a proprietary, novel DNA called immune-quiet DNA (iqDNA). iqDNA is an optimized variant of the company’s closed-ended DNA (ceDNA) that upon systemic administration with Generation Bio’s lipid nanoparticle (LNP) delivery has shown cytokine levels and tolerability comparable to chemically modified messenger RNA (mRNA) in mice and non-human primates (NHPs).

Intellia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.